Flu levels remain high in Ottawa, straining hospitals

Ottawa is facing a sustained influenza surge: wastewater influenza signals are four times higher than the same week in 2024–25 (down from 12x the prior week), emergency respiratory presentations are about 17% this year versus a three-year average of ~13% (peaking ~24% in mid-December), and in the week beginning Dec. 28 hospital admissions for flu were more than double those for COVID-19 and RSV combined. Hospitals are under pressure—Queensway Carleton Hospital reports being 16% over capacity with 29 patients boarded in the ED—and three children aged five to nine died from influenza complications in early December, creating operational strain that could affect elective care and local healthcare costs.

Analysis

Market structure: Acute flu pressure in Ottawa favors diagnostic makers (rapid PCR/antigen) and contingency staffing firms while pressuring hospital bed operators and elective-care revenue. Expect pricing power for rapid-test suppliers (e.g., ABT, RHHBY) and staffing agencies (AMN) for the next 4–12 weeks as inpatient demand runs ~25% above baseline at peak; hospital REITs/owners (e.g., MPW) face occupancy-driven revenue risk and higher operating costs.

Risk assessment: Tail risks include a more virulent/antiviral-resistant strain or provincial emergency measures that could cap test prices or reallocate supplies—low probability but high impact over 1–3 months. Immediate (days–weeks): capacity crunch and staffing scarcity; short-term (weeks–months): higher testing & staffing revenue but margin pressure in hospitals; long-term (quarters): seasonal normalization if vaccine uptake increases or new variant subsides. Hidden dependencies include provincial budget relief, labor-contract renewals, and supply-chain limits for antigen kits.

Trade implications: Direct tactical advantage to diagnostics and staffing for 1–3 months; consider options to express directionality with defined risk. Relative-value: long diagnostics/ staffing vs short hospital REITs/ elective-driven operators. Catalysts to watch: public-health wastewater metrics falling below 2x baseline, provincial funding announcements, and pharma vaccine-efficacy data within 30–90 days.

Contrarian angles: Consensus may underprice durable staffing-rate inflation—if staffing firms can sustain +5–15% rate hikes, earnings upgrades could follow for 2–4 quarters. Conversely, hospital distress could attract government backstops, compressing downside for REIT shorts. Historical analog: 2017–18 flu shocks boosted diagnostics/staffing for a quarter before reversion; watch for overextension in test-inventory build that would create a 3–6 month supply glut.

Key Decisions for Investors

• Establish a 2–3% long position in Abbott Laboratories (ABT) using a 3-month call spread (buy 3-month ITM call, sell higher strike) to capture increased rapid-test demand; target 20–40% upside, trim if Ottawa wastewater viral load drops to <2x baseline or hospital respiratory admissions return to ≤13%.
• Add a 2% long equity position in AMN Healthcare (AMN) to play acute staffing shortages; set stop-loss at -12% and target taking profits on a 30–60% rally or if published contract-rate inflation falls below +3% on two consecutive quarters.
• Initiate a 1–2% short position in Medical Properties Trust (MPW) or similar hospital-REIT exposure to capture occupancy-driven downside over 3–6 months; cover if provincial fiscal support/explicit subsidies are announced for hospital operations within 30 days.
• Deploy a 1% long basket (equal weights) of GSK (GSK) and Sanofi (SNY) equities to play incremental seasonal vaccine demand into the next 6 months; sell into strength if vaccine uptake surveys show >10 percentage-point improvement or WHO/PH confirms a benign season.
• Monitor Ottawa public-health triggers daily: act to reduce longs by 50% if wastewater influenza signal falls to ≤2x historical baseline or hospital respiratory admissions drop below a 13% three-year average for two consecutive weeks.